摘要
替诺福韦酯(TDF)是一种新型的无环核苷(酸)类似物,于2001年被美国FDA批准治疗人免疫缺陷病毒(HIV)的感染.目前TDF已经是广泛使用的治疗HIV的核苷(酸)类逆转录酶抑制剂之一.替诺福韦酯在临床实践中的效果,良好的适用性和合适的剂量均使其成为一线治疗的最流行药物之一.已有临床研究显示,TDF对合并感染HIV及乙型肝炎病毒(HBV)的患者具有较好的疗效.本文主要对TDF的研发背景、作用机制、药理学特点、不良反应、在CHB相关疾病方面的临床应用以及在治疗CHB的费用效能分析等方面的研究作一简要述评.
Tenofovir disoproxil fumarate （TDF） is an oral prodrug of tenofovir, a novel, acyclic nucleotide analogue with in vitro activity against HIV-1 and HIV-2. TDF is licensed by American Food and Drug Administration （FDA） in 2001 for the treatment of HIV infection. TDF is currently one of the most widely used nucleotide reverse transcriptase inhibitors （NRTIs） for the treatment of HIV infection. Its efficacy, favorable toxicity profile, and convenient dosing have made this drug one of the most popular first-line treatment. Numerous studies have demonstrated the use of TDF in the treatment of HIV infection. It also has been shown to be effective in HW/HBV coinfected patients and in patients with wild-type and lamivudine-resistant strains. Accumulating evidence suggests that TDF is more potent in suppressing HBV replication. In this review, we summarize the study progress of TDF in treating HBV infection.
出处
《世界华人消化杂志》
CAS
北大核心
2008年第24期2679-2688,共10页
World Chinese Journal of Digestology
关键词
乙型肝炎病毒
替诺福韦酯
慢性乙型肝炎
治疗
Hepatitis B virus
Tenofovir disoproxil fumarate
Chronic hepatitis B
Therapy
